Start på ZP's phase III glepaglutide- studie
-
Hvorfor stiger Zealand Pharma i dag?
Det kan være fordi at der i den amerikanske database over kliniske studier - clinicaltrials.gov - er blevet listet et nyt studie «Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS (EASE SBS 1)» per «October 1, 2018» og med en opdatering «October 1, 2018».
Studiet er angivet til ikke at indruller patienter endnu («Not yet recruiting») selvom Study Start Date er angivet til September 25, 2018. Jeg forventer at der ganske snart kommer en meddelse fra Zealand Pharma om at den først patient af de ialt 129 patienter er taget ind i studiet.
Studiet er angivet til at skulle være færdig October 23, 2020. Det vil sige om godt 2 år fra nu.
-
og nu kom meddelsen så
Zealand Pharma
Press release - No. 21/2018
Zealand Pharma enrolls first patient in Phase 3 trial with glepaglutide for the treatment of short bowel syndrome
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind